



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## COVID-19 and the anaesthetist: a Special Series

### Controversies in airway management of COVID-19 patients: updated information and international expert consensus recommendations

Huafeng Wei<sup>1,\*†</sup>, Bailin Jiang<sup>1,2,†</sup>, Elizabeth C. Behringer<sup>3</sup>, Ross Hofmeyr<sup>4</sup>, Sheila N. Myatra<sup>5</sup>, David T. Wong<sup>6</sup>, Ellen P. O' Sullivan<sup>7</sup>, Carin A. Hagberg<sup>8</sup>, Barry McGuire<sup>9</sup>, Paul A. Baker<sup>10</sup>, Jane Li<sup>11</sup>, Maksym Pylypenko<sup>12</sup>, Wuhua Ma<sup>13</sup>, Mingzhang Zuo<sup>14</sup>, Nuzhet M. Senturk<sup>15</sup> and Uwe Klein<sup>16</sup>

<sup>1</sup>Department of Anaesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA, USA, <sup>2</sup>Department of Anaesthesiology, Peking University People's Hospital, Beijing, China, <sup>3</sup>Division of Cardiovascular Surgery & Critical Care, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA, <sup>4</sup>Department of Anaesthesia & Perioperative Medicine, University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa, <sup>5</sup>Department of Anesthesiology, Critical Care and Pain, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India, <sup>6</sup>Department of Anesthesia, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, <sup>7</sup>Department of Anaesthesia and Intensive Care Medicine, St James's Hospital, Dublin, Ireland, <sup>8</sup>Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, <sup>9</sup>Department of Anaesthesia, Ninewells Hospital, Dundee, UK, <sup>10</sup>Department of Anaesthesia, Starship Children's Health, Auckland, New Zealand, <sup>11</sup>Department of Anaesthesia and Pain Management, Central Coast Local Health District, NSW, Australia, <sup>12</sup>Department of Anesthesiology and Intensive Care, Shupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine, <sup>13</sup>Department of Anesthesiology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China, <sup>14</sup>Department of Anaesthesiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China, <sup>15</sup>Istanbul Universitesi, Istanbul Tıp Fakültesi, Anesteziyoloji AD, Istanbul, Turkey and <sup>16</sup>Südharz-Klinikum Nordhausen, Nordhausen, Germany

\*Corresponding author. E-mail: [Huafeng.wei@penncare.upenn.edu](mailto:Huafeng.wei@penncare.upenn.edu)

†H. Wei and B. Jiang contributed equally to this article.

**Keywords:** airway management; COVID-19; healthcare workers; high-flow nasal oxygen; infection; mortality; personal protective equipment; SARS-CoV-2

As knowledge and experience in the management of critically ill coronavirus disease 2019 (COVID-19) patients has increased with time, a panel of international experts convened and formulated consensus opinions regarding controversial topics in advanced airway management based on current literature. Here we summarise updated information and international expert opinion on several controversial topics concerning airway management in critically ill patients with COVID-19.

## Personal protective equipment

Recommendations for the personal protective equipment (PPE) required during aerosol-generating procedures (AGPs), such as advanced airway management, are inconsistent amongst different countries and regions.<sup>1–8</sup> Two new studies report conflicting results, either supporting<sup>9</sup> or opposing<sup>10</sup> tracheal intubation and extubation as AGPs. Both studies were limited by small sample size, and used different definitions of AGPs and particle detection methods. Additional carefully designed studies are necessary to clarify the risk of aerosolised viral spread during tracheal intubation and extubation. In the interim, it is prudent to continue to consider both as AGPs. Maximal interventions to safeguard healthcare workers from cross infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) must be maintained until this question is adequately studied.

Studies from China have classified levels of PPE (Fig 1).<sup>11</sup> Level III has been reported to protect healthcare workers from cross infection during a variety of AGPs including tracheal intubation (Table 1),<sup>11,12,14,15</sup> high-flow nasal oxygen (HFNO) usage and tracheal intubation using a flexible intubating endoscope in patients with COVID-19.<sup>15</sup> Level II PPE, often used in other countries and regions outside China,<sup>4,5,7</sup> may not provide full protection from cross infection. Cross

infection rates in healthcare workers range from 0% to 14.7% (Table 1).<sup>27,28</sup> The primary difference between level II and III PPE is that level III includes use of a face shield, eye goggles, water-resistant gown, and hooded coverall. This assists in avoiding exposure of skin or eyes to air and potentially aerosolised viral particles (Fig 1). Table 2 summarises the commonly used levels of PPE around the world and the reported cross infection rates in healthcare workers. Videolaryngoscopy is the recommended approach for tracheal intubation in patients with COVID-19 in order to maximise first pass success rate and minimise exposure of healthcare workers during the procedure.<sup>1,12,13</sup> Awake tracheal intubation (ATI) has been performed successfully using flexible bronchoscopy. To date, cross infection of healthcare workers has not been reported during ATI. Therefore, ATI should be considered for management of the anticipated difficult airway, especially when tracheal intubation under general anaesthesia is considered unsafe.<sup>14</sup> Level III PPE should be used.

## Expert consensus

It appears that the higher the level of PPE used, the better the protection against cross infection. However, adequate protection of healthcare workers is often limited by the availability of PPE during a world pandemic. It is recommended to use the highest level of PPE available in the management of patients with COVID-19, especially during performance of high-risk AGPs such as tracheal intubation, extubation, or tracheostomy.<sup>1,12,17,37</sup> Fit testing and supervised donning and doffing of PPE remain critical steps in the avoidance of cross infection of healthcare workers. It is crucial to note that PPE must be a part of a comprehensive infection control strategy in order to be effective. Healthcare workers remain a precious resource in the fight against COVID-19.<sup>38</sup>




Fig 1. Classification of personal protective equipment.<sup>11,12,13</sup> Note an N95 mask respirator or surgical mask could be used inside the powered air purifying respirator (PAPR) hood to protect against potential self-contamination during doffing of personal protective equipment (PPE).

**Table 1** Healthcare workers cross infection rate at different levels of personal protective equipment. \*Tracheal intubation and other aerosol generating procedures. †No infection in operators with Level III PPE. ‡Total cases were not reported. §Total infection rate among asymptomatic HCWs. ¶The rate listed is the incidence of laboratory-confirmed COVID-19 diagnosis or new symptoms requiring self-isolation or hospitalisation after a tracheal intubation episode. This study included intubation in known and suspected COVID-19 patients. HCW, healthcare worker; PPE, personal protective equipment.

	Infection rate of HCWs after tracheal intubation	Overall infection rate of HCWs	Proportion of HCWs in confirmed COVID-19 cases
<b>China</b>			
Lack of protection Meng and colleagues <sup>13</sup>			29% (40/138)
<b>Level I</b>			
Lai and colleagues <sup>16</sup>		1.4% (93/6574)	
<b>Level II</b>			
Lai and colleagues <sup>16</sup>		0.5% (17/3110)	
<b>Level III<sup>3</sup></b>			
Wu and colleagues <sup>15</sup>	0% (0/6)		
Cai and colleagues <sup>14</sup>	0% (0/9)		
Yao and colleagues <sup>12</sup>	0% (0/52)		
Liu and colleagues <sup>17</sup>	0% (0/420)*		
<b>Levels I–III</b>			
Liu and colleagues <sup>11</sup>		2% (11/554)†	
Wu and colleagues <sup>18</sup>			3.8% (1716/44 672)
<b>Italy</b>			
<b>Level II<sup>7</sup></b>			
Livingston and Bucher <sup>19</sup>			9% (2026/22 512)
Li and colleagues <sup>20</sup>			>8% (>1116/13 882)
Anelli and colleagues <sup>21</sup>			9% (4824 HCWs)‡
<b>UK</b>			
<b>Level II<sup>6</sup></b>			
Treibel and colleagues <sup>22</sup>		11% (44/400)¶	
<b>USA</b>			
<b>Level II<sup>4</sup></b>			
Sullivan and colleagues <sup>23</sup>		14.7% (508/3466)	
Morcuende and colleagues <sup>24</sup>		12.1% (11/91)	
<b>South Africa</b>			
<b>Level II</b>			
Mendelson and colleagues <sup>25</sup>	0% (0/41)		
<b>International (17 countries)</b>			
<b>Level II<sup>5</sup></b>			

Continued

**Table 1 Continued**

	Infection rate of HCWs after tracheal intubation	Overall infection rate of HCWs	Proportion of HCWs in confirmed COVID-19 cases
El-Boghdadly and colleagues <sup>26</sup>	10.7% (184/1718)§		

### Use of high-flow nasal oxygen therapy

Many guidelines initially prohibited or discouraged use of high-flow nasal oxygen (HFNO) therapy in patients with COVID-19, based on the potential risks of aerosol generation and viral spread.<sup>1</sup> The extent of this risk remains unresolved.<sup>36</sup> Some studies support<sup>29,30</sup> use of HFNO whereas others do not (Table 2).<sup>31–33</sup> Use of HFNO in critically ill patients with COVID-19 with hypoxic respiratory insufficiency has been examined for its potential benefit as the mortality rate of mechanically ventilated patients remains high.<sup>39</sup> Patients with COVID-19 with pulmonary failure but normal lung compliance appear to respond favourably to HFNO treatment, but those patients with impaired lung compliance may not derive the same benefit.<sup>40</sup> A cohort study from the 2009 epidemic of respiratory failure caused by influenza A found that use of HFNO reduced the need for mechanical ventilation by 45%.<sup>34</sup> The future use of HFNO in patients with COVID-19 will be based on its efficacy to diminish hypoxaemia, the need for mechanical ventilatory support, and mortality.

Use of appropriate PPE, and supervised donning and doffing, are critical in avoiding cross infection from any AGP. Other factors, such as negative pressure rooms, high air exchange rates through the ventilation system, the ventilation system itself, and use of an anteroom, are additional important interventions to reduce the risks of cross infection. The use of HFNO for apnoeic oxygenation during laryngoscopy and tracheal intubation is recommended for selected patients with COVID-19 at high risk of hypoxaemia.<sup>15</sup>

Another controversy associated with the use of HFNO is the concomitant use of a simple surgical mask as a means to minimise dispersion of aerosols in spontaneously breathing patients with COVID-19. A preliminary study using computational fluid dynamic simulation determined that addition of a surgical mask over a properly fitted HFNO device may be an effective option to reduce droplet deposition from exhaled gas flow.<sup>41</sup> A recent study of healthy volunteers evaluated aerosol production with HFNO and noninvasive positive pressure ventilation (NIPPV) compared with 6 L min<sup>-1</sup> low-flow nasal oxygen (LFNO).<sup>35</sup> HFNO and LFNO were studied with and without subjects wearing a type 1 surgical face mask. Aerosol size and mass were measured at 2 and 6 ft from the patient's nasopharynx. There was no significant difference in aerosol production between HFNO, NIPPV, or LFNO. The use of a surgical mask over the HFNO device did not change aerosolised particle spread.<sup>35</sup> Further study is critical to confirm the safety and efficacy of the practice of applying a mask over HFNO devices. Barotrauma is a risk when HFNO is delivered simultaneously with a tightly sealed face mask, such as an anaesthesia face mask, owing to excessive delivered pressure, so this combination should be avoided.<sup>42</sup>

**Table 2** Studies on use of high-flow nasal oxygen (HFNO) therapy and risks of viral spread. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Authors	Type of study	Subject	Details
<i>Restrict use</i> Santarpia and colleagues <sup>29</sup>	Clinical observation	SARS-CoV-2	The highest concentrations of virus in air were recorded during oxygenation through a nasal cannula.
Loh and colleagues <sup>30</sup>	Simulation study	SARS-CoV-2	HFNO increased the dispersion distance of cough-generated droplets
<i>Support use</i> Leung and colleagues <sup>31</sup>	Randomised controlled crossover trial	Gram-negative bacteria	HFNO was not associated with increased air or contact surface contamination by bacteria in ICU patients
Hui and colleagues <sup>32</sup>	Simulation study	Respiratory virus	HFNO with good interface fitting was associated with limited exhaled air dispersion of virus
Tran and colleagues <sup>33</sup>	Systematic review	SARS-CoV	HFNO did not increase transmission risk significantly
Rello and colleagues <sup>34</sup>	Cohort study	H1N1v	No secondary infections in healthcare workers, nor nosocomial pneumonia occurred during HFNO therapy
Miller and colleagues <sup>35</sup>	Volunteer simulation study	Aerosol production	No significant difference in aerosol production between either HFNO and low-flow nasal cannula
<i>Neutrality</i> Agarwal and colleagues <sup>36</sup>	Systematic review	SARS-CoV-2	Unknown effects of HFNO on risk of virus spreading

### Expert consensus

There is currently no convincing evidence that HFNO increases the risk of COVID-19 cross infection to healthcare workers. Well-designed prospective studies are warranted to clarify the risk, if any, and to assess risk-reducing interventions. It is recommended that use of HFNO in patients with COVID-19 depends on the risk/benefit ratio determined by the clinician for each patient until additional information is available.

### Early or late tracheal intubation

Recent studies<sup>1,2,12,43</sup> have recommended early tracheal intubation to minimise the risk of cross infection of healthcare workers. Early tracheal intubation may obviate the need for urgent intubation and may lessen the severity of hypoxaemia and haemodynamic instability during induction of anaesthesia and tracheal intubation. Results of the combined use of noninvasive respiratory support and awake prone positioning,<sup>44</sup> particularly in patients with the type L (high compliance) acute respiratory distress syndrome (ARDS), are encouraging.<sup>40</sup> A recent report showed a significant decrease in the mortality rate of patients admitted to ICU with COVID-19. This is likely attributable to multiple factors, including increased clinical experience, rapidly developing management strategies and therapeutics and increased use of noninvasive ventilatory support such as HFNO.<sup>45</sup> Use of HFNO may delay tracheal intubation and mechanical ventilation, and reduce the need for admission to ICU.<sup>36,46–48</sup>

### Expert consensus

This controversy regarding early vs late tracheal intubation is still evolving.<sup>49</sup> It is recommended that the appropriate time to

intubate patients with COVID-19 may be dependent on their individual pathology and pathophysiology, the acute trajectory of their illness, in addition to their responsiveness to trials of noninvasive airway management.

### Summary

Level III PPE appears to provide healthcare workers with maximum protection against cross infection by aerosolised SARS-CoV-2 viral particles. The highest level of PPE should be considered in the management of patients with COVID-19, especially during performance of AGPs. Global efforts should provide adequate levels of PPE for all healthcare workers during the pandemic and uniform application of environmental controls. Use of HFNO should be considered for management of acute respiratory failure and after tracheal extubation of patients with COVID-19 as long as optimal environmental measures and protective PPE are available for healthcare workers. Noninvasive ventilation is encouraged as the first-line approach before tracheal intubation and mechanical ventilation in critically ill patients with COVID-19 with the aforementioned caveats, although further study of this approach is warranted.

### Authors' contributions

All authors were involved in the conception and writing of manuscript

### Declarations of interest

HW is a consultant of Well Lead Medical Company, Guangzhou, Guangdong, China. PAB has received travel assistance and funding for research from Fisher and Paykel Healthcare.

## Acknowledgements

We thank David Gabrielsen (Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA, USA) for his assistance with preparing Fig 1. We thank International Airway Management Society (IAMS) for organizing two virtual meetings contributing to the international expert consensus recommendations.

## References

- Cook TM, El-Boghdadly K, McGuire B, McNarry AF, Patel A, Higgs A. Consensus guidelines for managing the airway in patients with COVID-19: guidelines from the difficult airway society, the association of anaesthetists the intensive care society, the faculty of intensive care medicine and the royal college of anaesthetists. *Anaesthesia* 2020; **75**: 785–99
- Brewster DJ, Chrimes N, Do TB, Fraser K, Groombridge CJ. Consensus statement: safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group. *Med J Aust* 2020; **212**: 472–81
- Zuo MZ, Huang YG, Ma WH, et al. Expert recommendations for tracheal intubation in critically ill patients with novel coronavirus disease 2019. *Chin Med Sci J* 2020; **35**: 105–9
- US Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic. Available online at <https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html>. [Accessed 18 November 2020].
- World Health Organization. *Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19): interim guidance*, 19 March 2020. Available online at, [https://apps.who.int/iris/bitstream/handle/10665/331498/WHO-2019-nCoV-IPCPE\\_use-2020.2-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/331498/WHO-2019-nCoV-IPCPE_use-2020.2-eng.pdf). [Accessed 18 November 2020]
- Public Health England. COVID-19: infection prevention and control. Published 10 January 2020, update 20 October 2020. Available online at, <https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control>. [Accessed 18 November 2020]
- European Centre for Disease Prevention and Control (ECDC). *Personal protective equipment (PPE) needs in healthcare settings for the care of patients with suspected or confirmed novel coronavirus (2019-nCoV)* Feb 7, 2020. Available from, <https://www.ecdc.europa.eu/sites/default/files/documents/novel-coronavirus-personal-protective-equipment-needs-healthcare-settings.pdf>. [Accessed 8 September 2020]
- Şentürk M, El Tahan MR, Szegedi LL, et al. Thoracic anesthesia of patients with suspected or confirmed 2019 novel coronavirus infection: preliminary recommendations for airway management by the European Association of Cardiothoracic Anaesthesiology Thoracic Subspecialty Committee. *J Cardiothorac Vasc Anesth* 2020; **34**: 2315–27
- Dhillon RS, Rowin WA, Humphries RS, et al. Aerosolisation during tracheal intubation and extubation in an operating theatre setting. *Anaesthesia* 2020. <https://doi.org/10.1111/anae.15301>. advance. Access Published October 12
- Brown J, Gregson FKA, Shrimpton A, et al. A quantitative evaluation of aerosol generation during tracheal intubation and extubation. *Anaesthesia* 2020. <https://doi.org/10.1111/anae.15292>. Advance Access Published October 6
- Liu Z, Wu Z, Zhao H, Zuo M. Personal protective equipment during tracheal intubation in patients with COVID-19 in China: a cross-sectional survey. *Br J Anaesth* 2020; **125**: e420–2
- Yao W, Wang T, Jiang B, et al. Emergency tracheal intubation in 202 patients with COVID-19 in Wuhan, China: lessons learnt and international expert recommendations. *Br J Anaesth* 2020; **125**: e28–37
- Meng L, Qiu H, Wan L, et al. Intubation and ventilation amid the COVID-19 outbreak: wuhan's experience. *Anesthesiology* 2020; **132**: 1317–32
- Cai SJ, Wu LL, Chen DF, et al. [Analysis of bronchoscope-guided tracheal intubation in 12 cases with coronavirus disease 2019 under the personal protective equipment with positive pressure protective hood]. *Zhonghua Jie He He Hu Xi Za Zhi* 2020; **43**: 332–4
- Wu CN, Xia LZ, Li KH, et al. High-flow nasal-oxygenation-assisted fiberoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial. *Br J Anaesth* 2020; **125**: e166–8
- Lai X, Wang M, Qin C, et al. Coronavirus disease 2019 (COVID-2019) infection among health care workers and implications for prevention measures in a tertiary hospital in Wuhan, China. *JAMA Netw Open* 2020; **3**, e209666
- Liu M, Cheng SZ, Xu KW, et al. Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study. *BMJ* 2020; **369**: m2195
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020; **323**: 1239–42
- Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. *JAMA* 2020; **323**: 1335
- Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. *Eur Respir J* 2020; **55**: 2000892
- Anelli F, Leoni G, Monaco R, et al. Italian doctors call for protecting healthcare workers and boosting community surveillance during covid-19 outbreak. *BMJ* 2020; **368**: m1254
- Treibel TA, Manisty C, Burton M, et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital. *Lancet* 2020; **395**: 1608–10
- Sullivan EH, Gibson LE, Berra L, Chang MG. In-hospital airway management of COVID-19 patients. *Crit Care* 2020; **24**: 292
- Morcuende M, Guglielminotti J, Landau R. Anesthesiologists' and intensive care providers' exposure to COVID-19 infection in a New York City academic center: a prospective cohort study assessing symptoms and COVID-19 antibody testing. *Anesth Analg* 2020; **131**: 669–76
- Mendelson M, Bokolo L, Boutall A, et al. Clinical management of COVID-19: experiences of the COVID-19 epidemic from groote schuur hospital. *S Afr Med J* 2020; **110**: 968–72
- El-Boghdadly K, Wong DJN, Owen R, et al. Risks to healthcare workers following tracheal intubation of patients with COVID-19: a prospective international multicentre cohort study. *Anaesthesia* 2020. <https://doi.org/10.1111/anae.15170>. Advance Access Published June 9

27. Feldman O, Meir M, Shavit D, Idelman R, Shavit I. Exposure to a surrogate measure of contamination from simulated patients by emergency department personnel wearing personal protective equipment. *JAMA* 2020; **323**: 2091–3
28. Cook TM. Risk to health from COVID-19 for anaesthetists and intensivists — a narrative review. *Anaesthesia* 2020; **75**: 1494–508. <https://doi.org/10.1111/anae.15220>. Advance Access. Published July 17
29. Santarpia JL, Rivera DN, Herrera VL, et al. Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care. *Sci Rep* 2020; **10**: 12732
30. Loh NW, Tan Y, Taculod J, et al. The impact of high-flow nasal cannula (HFNC) on coughing distance: implications on its use during the novel coronavirus disease outbreak. *Can J Anaesth* 2020; **67**: 893–4
31. Leung CCH, Joynt GM, Gomersall CD, et al. Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial. *J Hosp Infect* 2019; **101**: 84–7
32. Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. *Eur Respir J* 2019; **53**: 1802339
33. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. *PLoS One* 2012; **7**, e35797
34. Rello J, Pérez M, Roca O, et al. High-flow nasal therapy in adults with severe acute respiratory infection: a cohort study in patients with 2009 influenza A/H1N1v. *J Crit Care* 2012; **27**: 434–9
35. Miller DC, Beamer P, Billheimer D, et al. Aerosol risk with noninvasive respiratory Support in patients with COVID-19. *J Am Coll Emerg Physicians Open* 2020; **1**: 521–6
36. Agarwal A, Basmaji J, Muttalib F, et al. High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. *Can J Anaesth* 2020; **67**: 1217–48
37. Gosling AF, Bose S, Gomez E, et al. Perioperative considerations for tracheostomies in the era of COVID-19. *Anesth Analg* 2020; **131**: 378–86
38. Assunção M. More than 1,000 U.S. health workers have died of COVID-19; many were racial minorities, immigrants. *New York Daily News*; 2020 Aug 26. Available from, <https://www.nydailynews.com/coronavirus/ny-coronavirus-health-workers-died-covid-racial-minorities-immigrants-20200826-xklqztr5ngylg2bkk3phj237y-story.html>. [Accessed 8 September 2020]
39. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region — case series. *N Engl J Med* 2020; **382**: 2012–22
40. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? *Intensive Care Med* 2020; **46**: 1099–102
41. Leonard S, Atwood Jr CW, Walsh BK, et al. Preliminary findings on control of dispersion of aerosols and droplets during high-velocity nasal insufflation therapy using a simple surgical mask: implications for the high-flow nasal Cannula. *Chest* 2020; **158**: 1046–9
42. Fisher & Paykel Healthcare. Optiflow thrive-optiflow oxygen kit AA400, optiflow filtered nasal cannula AA001M. Product information.
43. Brown 3rd CA, Mosier JM, Carlson JN, Gibbs MA. Pragmatic recommendations for intubating critically ill patients with suspected COVID-19. *J Am Coll Emerg Physicians Open* 2020; **1**: 80–4
44. Coppo A, Bellani G, Winterton D, et al. Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study. *Lancet Respir Med* 2020; **8**: 765–74
45. Armstrong RA, Kane AD. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. *Anaesthesia* 2020; **75**: 1340–9
46. Geng S, Mei Q, Zhu C, et al. High flow nasal cannula is a good treatment option for COVID-19. *Heart Lung* 2020; **49**: 444–4445
47. Gürün Kaya A, Öz M, Erol S, Çiftçi F, Çiledağ A, Kaya A. High flow nasal cannula in COVID-19: a literature review. *Tuberk Toraks* 2020; **68**: 168–74
48. Lagi F, Piccica M, Graziani L, et al. Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020. *Euro Surveill* 2020; **25**: 2000556
49. Hernandez-Romieu AC, Adelman MW, Hockstein MA, et al. Timing of intubation and mortality among critically ill coronavirus disease 2019 patients: a single-center cohort study. *Crit Care Med* 2020; **48**: e1045–53